CZI's philosophy is to pursue transformative, paradigm-shifting medical advances. The organization explicitly avoids incremental improvements, such as extending a cancer patient's life by a few months. Instead, it directs all its resources towards ambitious goals like outright curing or preventing diseases, fostering a culture of "unbridled ambition."
Related Insights
True quantum leaps are not incremental improvements but massive, non-linear jumps forward. A proper goal in this context should feel absurdly ambitious and even frightening, as it forces a complete change in your operational methods.
The endgame for CZI's work is hyper-personalized, "N of one" medicine. Instead of the current empirical approach (e.g., trying different antidepressants for months), AI models will simulate an individual's unique biology to predict which specific therapy will work, eliminating guesswork and patient suffering.
CZI’s mission to cure all diseases is seen as unambitious by AI experts but overly ambitious by biologists. This productive tension forces biologists to pinpoint concrete obstacles and AI experts to grasp data complexity, accelerating the overall pace of innovation.
CZI focuses on creating new tools for science, a 10-15 year process that's often underfunded. Instead of just giving grants, they build and operate their own institutes, physically co-locating scientists and engineers to accelerate breakthroughs in areas traditional funding misses.
CZI set an audacious goal to cure all disease. When scientists deemed it impossible, CZI's follow-up question, "Why not?" revealed the true bottleneck wasn't funding individual projects, but a systemic lack of shared tools, which then became their core focus.
CZI targets a 10-15 year time horizon for its major scientific initiatives. This is a strategic sweet spot, similar to a venture-backed company's lifecycle, which is long enough for ambitious goals but concrete enough for a team to see a project through.
CZI operates at the intersection of two cultures: biologists who saw their goals as "crazy ambitious" and AI experts who saw them as "boring" and inevitable. Their strategy is to actively merge these fields to create breakthroughs that neither could achieve alone.
Instead of funding small, incremental research grants, CZI's philanthropic strategy focuses on developing expensive, long-term tools like AI models and imaging platforms. This provides leverage to the entire scientific community, accelerating the pace of the whole field.
CZI's goal to cure all diseases by 2100 is seen as unambitious by AI experts but overly ambitious by biologists. This difference in perspective forces biologists to define barriers and AI researchers to understand data complexities, fostering a more credible, grounded approach to innovation.
CZI strategically focuses on developing long-term scientific tools and platforms by operating its own labs. This addresses a funding gap left by government grants for individual investigators and public-health-focused philanthropies, aiming to accelerate research for all scientists.